MTVA: 8-Week Data for 48 mg Cohort in Phase 1 Obesity Study Expected Before End of 2025
On November 6, 2025, MetaVia Inc. (MTVA) announced financial results for the third quarter of 2025 and provided a business update. We anticipate...
193 Views
MTVA: Results from 8-week Study of 48 mg DA-1726 Expected Before End of 2025
On August 7, 2025, MetaVia Inc. (MTVA) announced financial results for the second quarter of 2025 and provided a business update. The company...
163 Views
Dong A St (170900 KS): Five Reasons Why Performance Improvement Is Expected
​Dong A St sees double-digit revenue growth in 1Q25. Strong existing operation and forthcoming launches to fuel growth. Pipeline is promising, with...
320 Views
MTVA: DA-1241 in Combination with Efruxifermin Shows Additive Hepatoprotective Effects in Mouse MASH Model
On June 21, 2025, MetaVia Inc. (MTVA) announced the presentation of preclinical data for DA-1241, the company's novel GPR119 agonist, that showed...
321 Views
MTVA: Additional Positive Topline Results for DA-1726 in Phase 1 MAD Study
On May 14, 2025, MetaVia Inc. (MTVA) announced financial results for the first quarter and provided a business update. The company recently...
253 Views